Switching To Gilenya® (Fingolimod) From Standard Interferon Offers Sustained Freedom From Disease Activity For People With Relapsing Remitting MS

Two new analyses from the pivotal Phase III TRANSFORMS study presented at the European Neurological Society (ENS) have shown early and sustained improvements in disease activity in patients who were switched from an interferon to Gilenya® (fingolimod). Improvements were seen within 12 months of the switch and were sustained up to 4.5 years, confirming the long term effectiveness of once daily pill fingolimod...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news